Advantage Multi

Verify with FDA CVM →

58 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
58
Total Reports
3
Deaths Reported
520.0%
Death Rate

Active Ingredients

Advantage Multi

Administration Routes

TopicalUnknownOral

Species Affected

Dog 54
Cat 4

Most Affected Breeds

Retriever - Labrador 6
Chihuahua 5
Crossbred Canine/dog 4
Boxer (German Boxer) 2
Siberian Husky 2
Black Mouth Cur 2
Terrier (unspecified) 2
Retriever - Golden 2
Shepherd Dog - Australian 2
Greyhound 2

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 41
Overdose 4
Decreased appetite 4
Elevated total bilirubin 4
Weight loss 4
Anaemia NOS 3
Neutropenia 3
Lymphopenia 3
Hypoproteinaemia 3
Anxiety 2
Other abnormal test result NOS 2
Drug dose administration interval too long 2

Outcome Breakdown

Ongoing
41 (70.7%)
Outcome Unknown
13 (22.4%)
Died
2 (3.4%)
Euthanized
1 (1.7%)
Recovered/Normal
1 (1.7%)

Data Summary

Metric Value
Total adverse event reports 58
Reports involving death 3
Case-fatality rate (reported events) 520.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Advantage Multi Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 58 adverse event reports referencing Advantage Multi, including 3 reports in which the animal died — a 520.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Advantage Multi. Reported administration routes include Topical, Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Advantage Multi reports are Dog (54 reports), Cat (4 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (6), Chihuahua (5), Crossbred Canine/dog (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Advantage Multi are Lack of efficacy (endoparasite) - heartworm (41), Overdose (4), Decreased appetite (4), Elevated total bilirubin (4). Of the 58 reports with a coded outcome, Ongoing is the leading category at 70.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Advantage Multi.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial